Massive Bio

Empowering cancer patients globally through our AI-based, clinical trial matching platform, always 100% free. Providing options & hope.

[Massive Bio @MassiveBio]

Most lung cancer patients flagged at high risk during imaging never make it to a clinical trial.

Massive Bio + Optellum are closing that gap.

Optellum's FDA-cleared AI surfaces high-risk nodule patients early. We match them to active NSCLC trials and get the right information to their physicians, in real time.

Full story: https://t.co/lmkp1LjS81

#LungCancer #NSCLC #ClinicalTrials #AIHealth

[Massive Bio @MassiveBio]

Our Co-Founder and CEO Selin Kurnaz is en route from ASCO 2026 to the @Jefferies Healthcare Investment Conference in New York City, and the momentum from Chicago is following her there.

American Society of Clinical Oncology (ASCO) 2026 was a defining week for Massive Bio. Nearly 200 meetings. Four press releases. Six new product launches. Remarkable traction across our clinical, commercial, and real world data business lines, and meaningful engagement with every layer of the oncology ecosystem: FDA, NCI, pharmaceutical companies, payers, providers, and patients.

This is what strengthening market leadership looks like.

The conference is over but the work continues.

#ASCO26 #Oncology #ClinicalTrials #CancerCare #HealthcareInnovation #JefferiesHealthcare

[Massive Bio @MassiveBio]

Day 3 at #ASCO2026, and the energy at Booth #IH04 has been incredible.

Following yesterday's announcement of the Reticulum Nexus™ product suite, we've had the privilege of connecting with researchers, clinicians, and innovators from across the globe, all united by the same mission: getting the right patients to the right trials, faster.

Tomorrow, June 1st, our Co-Founder & Chief Medical AI Officer, Arturo LoAIza-Bonilla MD (@DrArturoAI), will be presenting at Session S403:

🗓 "Practical Playbook for Artificial Intelligence, Screening, and Remote Oncology in Resource-Constrained Settings" 🕤 9:45 - 10:00 AM CDT

If you're at McCormick Place, stop by Booth #IH04, we'd love to connect.

#ASCO26 #PrecisionOncology #ClinicalTrials #AI #Oncology

[Massive Bio @MassiveBio]

ASCO 2026 is here, and so are we.

We're live at Booth #IH04 in the Innovation Hub at McCormick Place, #Chicago, and the conversations have already started. The booth is buzzing, the energy is incredible, and seeing so many brilliant minds gathered around one shared mission is exactly why we do this.

This year, we're showing what it actually looks like when AI moves beyond matching and into full orchestration. Sentinel Agents™ monitoring in real time. NexusPulse™ Intelligent Calculators turning clinical signals into next actions. DrArturo AI™ and Phoebe AI™ supporting clinicians and patients at every step. TrialRelay™ making sure no referral disappears into the void. All of it connected, all of it inside Reticulum Nexus™.

American Society of Clinical Oncology (ASCO) brings the entire oncology ecosystem under one roof, and we're grateful to be part of it, made possible in part by the incredible organizations that make this conference happen, including Bristol Myers Squibb (@bmsnews) , Daiichi Sankyo US(@DaiichiSankyoUS), Genentech (@genentech), Gilead Sciences (@GileadSciences) , Eli Lilly and Company (@EliLillyandCo), and more.

If you're here, come find us. Let's talk.

Schedule a meeting with us: https://t.co/lWHdWdhxWq

📍 Booth #IH04, Innovation Hub, McCormick Place

#ASCO2026 #PrecisionOncology #ClinicalTrials

[Arturo LoAIza-Bonilla, MD MSEd @DrArturoAI]

Another reason why #ASCO26 is so special is how we all come together to find each other for collaborations, research, science, and R&D. Even better when meeting with @ASCO staff, friends, colleagues, mentors and mentees. Hearts are full, science is shared, the best of humanity represented in the fight against cancer (and of course, AI 😉) @mystlukes @MassiveBio

[Massive Bio @MassiveBio]

Today at #ASCO2026, Massive Bio announced the next-generation Reticulum Nexus™ suite, Patient Connect™, TrialRelay™, NexusPulse™, Sentinel Agents™, DrArturo AI™, and Phoebe AI™ working together in real-time to move patients from matching to enrollment.

Full announcement: https://t.co/X0ftrl29MM

#OncologyAI #ClinicalTrials #PrecisionOncology

[Massive Bio @MassiveBio]

Massive Bio has partnered with @TOUCHBBCA and @NavigatingTrials to bring AI-powered clinical trial matching directly to cancer patient communities.

Because finding the right trial shouldn't be this hard.

Read more: https://t.co/tgEipHmXNx

#ClinicalTrials #CancerCare #HealthEquity

[Massive Bio @MassiveBio]

At #ASCO2026, Massive Bio is unveiling the next phase of Reticulum Nexus, our multi-agent AI operating system for oncology access.

Not a chatbot. Not a dashboard. Infrastructure.
Booth #IH04, Innovation Hub.

🔗 https://t.co/Gk1wpozC5M

🔗 https://t.co/LF984qUtfQ

#ASCO2026 #OncologyAI #ClinicalTrials

[Massive Bio @MassiveBio]

We arrive in #Chicago in 2 days.

It's been a milestone year. A landmark peer-reviewed study across 3,800+ cancer patients. Our collaboration with @OpenAI. Partnerships with BeeKeeperAI, Just Worldwide (@JWWMedResearch) Worldwide, and more. A Digital Medicine Society (DiMe) Seal recipient and listed in the Centers for Medicare & Medicaid Services Medicare App Library, reaching over 68 million Medicare beneficiaries.

And we're not done. Some of our biggest announcements are coming during and after #ASCO2026.

Find us at Booth #IH04 in the Innovation Hub, or schedule time with the team before the doors open:

🔗 https://t.co/3d4C6MERIP

📍 McCormick Place, Chicago · May 29 – June 2

#ASCO26 #OncologyInnovation #ClinicalTrials #PrecisionOncology

[Massive Bio @MassiveBio]

We're expanding access to oncology clinical trials for underserved communities, with privacy built in from the start.

Massive Bio has deployed its AI-powered pre-screening capabilities through BeeKeeperAI's EscrowAI® platform, leveraging federated confidential computing to match cancer patients to clinical trials without ever moving their sensitive data outside the healthcare provider's environment.

The program initially focuses on the #Atlanta, #Georgia region, working to reach historically underrepresented patient populations who may otherwise never learn about trials they qualify for.

This is what equitable, scalable clinical research looks like: AI traveling to the data, not the other way around.

🔗 Read the full announcement: https://t.co/70DIrGqNSm

[Massive Bio @MassiveBio]

Today, May 20, is International Clinical Trials Day.

Clinical trials are how medicine moves forward. But for too long, finding the right trial has been one of the hardest parts of a cancer diagnosis.

At Massive Bio, we exist to change that. Our AI has matched over 190,000 patients to clinical trials across 17 countries, so that geography, complexity, and time never stand between a patient and a potentially life-changing option.

Every match matters. Every trial matters. Every patient matters.

#InternationalClinicalTrialsDay #ClinicalTrials #OncologyInnovation #CancerCare

[Massive Bio @MassiveBio]

Germany, we're here. 🇩🇪

Our Co-Founder, CTO & COO Çağatay Çulcuoğlu is at DataForum today in Mainz, joining researchers, clinicians, lawyers, and data infrastructure experts for a full afternoon of talks and hands-on exchange around one of healthcare's most pressing challenges: turning health data into real-world impact.

From the EU Health Data Space to real-world evidence, data governance to clinical research infrastructure — the conversations happening today matter deeply to what we build at Massive Bio every day.

See you at KUZ. 👋

📅 May 19 | KUZ – Kulturzentrum Mainz, Germany
#DataForum #HealthData #DigitalHealth #RealWorldData

[Massive Bio @MassiveBio]

Our Co-Founder and CEO Selin Kurnaz, PhD was in #Nashville for the AGC Partners HCIT & Life Sciences Technology Summit, with 16 investor meetings in a single day.

The investment landscape for healthcare AI is shifting. Traditional software models are being re-evaluated, consolidation is on the horizon, and the platforms that own a vertical with direct patient-consented data at their core are the ones positioned to lead.

Massive Bio is at the center of that shift.

Hear Selin's take on what investors are signaling and what it means for the road ahead, and visit https://t.co/dpOy6AtxAK to see what Massive Bio is bringing to #ASCO2026 and schedule a meeting.

#HealthcareAI #Oncology #ClinicalTrials #HealthTech #PrecisionOncology #ASCO2026 #ASCO26

[Massive Bio @MassiveBio]

Massive Bio and Just Worldwide are partnering to connect more cancer patients to clinical trial opportunities — through patient communities, advocacy groups, and AI-driven trial matching.

Only 3–5% of cancer patients ever enroll in a clinical trial. The barrier is rarely eligibility. It is awareness, access, and trust. Just Worldwide brings deep engagement with patient communities — including underrepresented populations — at a scale that traditional recruitment methods cannot reach. Massive Bio brings the AI infrastructure to match those patients to the right trials at the right moment.

Together, we are closing the gap between patients who qualify and trials that need them.

"As oncologists, we know that the right clinical trial can be a turning point for a patient — but only if they know it exists. Just Worldwide's ability to engage patients and advocacy communities at scale, combined with Massive Bio's AI matching engine, creates a system where the right information finds the right patient at exactly the right moment in their journey."

— Arturo Loaiza-Bonilla, MD, Co-Founder & Chief Medical AI Officer, Massive Bio

🔗 https://t.co/n0ubE6wBYv

@MassiveBio @JWWMedResearch @DrArturoAI

#ClinicalTrials #Oncology #AIinOncology #CancerCare #PatientAccess #HealthEquity #PrecisionOncology

[Massive Bio @MassiveBio]

Happy Mother's Day to every mom out there. 💙

The ones who stayed up late worrying. The ones who fought battles no one saw. The ones who kept goin, no matter what.

At Massive Bio, we think of mothers every day. They're why we work to make sure no cancer patient runs out of options.

#MothersDay #MassiveBio #CancerCare #ClinicalTrials #HappyMothersDay

[Massive Bio @MassiveBio]

Massive Bio was featured in Genetic Engineering & Biotechnology News (@GENbio) as part of a deep dive into how AI is reshaping drug discovery and clinical research.

The piece covers a broader shift: big tech is building AI platforms purpose-built for scientific workflows. The inference inflection has arrived in biopharma.

For us, this reinforces what we've been building, AI-driven infrastructure that matches cancer patients to clinical trials with the speed and rigor oncology demands.

🔗: https://t.co/YT6WF0sOCY

[500 Global @500GlobalVC]

As AI reshapes healthcare, one of its most meaningful impacts is breaking down barriers to access — ensuring the right patients can find the right treatments at the right time.

@MassiveBio's partnership with @OpenAI is a powerful step in that direction. By transforming complex clinical trial protocols into machine-readable formats, the team is enabling real-time, automated patient pre-screening at scale.

"By collaborating with OpenAI, we are transforming how trials are interpreted and operationalized. This is infrastructure-level deployment that can close the gap between the thousands of open trials and the millions of patients who never learn they may qualify." — Co-founder & Chief Medical AI Officer Arturo LoAIza-Bonilla MD.

Read the full story: https://t.co/OsG8CUFo9C

@christine_tsai @TonyW @vishalharnal @atxfrench @leoclee

[Massive Bio @MassiveBio]

What does it actually take to rewire health delivery at scale, not just regionally, but globally?

Our Co-Founder & Chief Medical AI Officer, Dr. Arturo LoAIza-Bonilla MD (@DrArturoAI), joined Fern Lazar (@fernlazar) at the @1businessworld Global Health & Purpose Summit to tackle exactly that.

In their session "From Innovation to Impact: Rewiring Global and Regional Health Delivery at Scale," Arturo and Fern explored how AI-driven precision oncology is bridging the gap between breakthrough innovation and real-world patient outcomes, across borders, healthcare systems, and clinical realities.

At @MassiveBio, that's not a vision statement. It's what we build every day.

🎥 Watch the full session → https://t.co/ezd8VUDybr

#GlobalHealth #PrecisionOncology #HealthcareAI #ClinicalTrials